Tokyo Tape
Sign in
← Nihon Chouzai

Half-year report · Q2

3341.TEDINET S100URMJ
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥175.6bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥340.3bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥166.3bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥423m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.4bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥772m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.4bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.4bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥762m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥43m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥43m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥204.1bnat 2024-09-30Cons.Assets
Total assets¥195.1bnat 2024-03-31Cons.Assets
Total assets¥193.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥146.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥136.7bnat 2024-03-31Cons.Liabilities
Net assets / equity¥57.9bnat 2024-09-30Cons.Net assets
Net assets / equity¥58.4bnat 2024-03-31Cons.Net assets
Net assets / equity¥57.9bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥26.4bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥26.0bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥26.4bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.0bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥22.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.8bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥20.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥8.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥4.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-1.442024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.352023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥58.442023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio28.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.9%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio29.9%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥6.6bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥6.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥156.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥156.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.5bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥122m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥766m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥19.6bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥652m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥182.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥175.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥4.6bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥3.5bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥14m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥698m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥167m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥173.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥166.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥6.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 520
ItemContextValueUnit
Other clPrior1YearInstant10786000000JPY
Other clCurrentQuarterInstant8374000000JPY
Current liabilitiesPrior1YearInstant84858000000JPY
Current liabilitiesCurrentQuarterInstant93000000000JPY
Long term loans payablePrior1YearInstant42108000000JPY
Long term loans payableCurrentQuarterInstant43328000000JPY
Provision for directors retirement benefitsPrior1YearInstant85000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant77000000JPY
Net defined benefit liabilityPrior1YearInstant2587000000JPY
Net defined benefit liabilityCurrentQuarterInstant2683000000JPY
Other nclPrior1YearInstant7095000000JPY
Other nclCurrentQuarterInstant7171000000JPY
Noncurrent liabilitiesPrior1YearInstant51876000000JPY
Noncurrent liabilitiesCurrentQuarterInstant53261000000JPY
LiabilitiesPrior1YearInstant136735000000JPY
LiabilitiesCurrentQuarterInstant146261000000JPY
Capital stockPrior1YearInstant3953000000JPY
Capital stockCurrentQuarterInstant3953000000JPY
Capital surplusPrior1YearInstant9228000000JPY
Capital surplusCurrentQuarterInstant9228000000JPY
Retained earningsPrior1YearInstant47020000000JPY
Retained earningsCurrentQuarterInstant46602000000JPY
Treasury stockPrior1YearInstant-1898000000JPY
Treasury stockCurrentQuarterInstant-1946000000JPY
Shareholders equityPrior1YearInstant58303000000JPY
Shareholders equityCurrentQuarterInstant57837000000JPY
Remeasurements of defined benefit plansPrior1YearInstant48000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant48000000JPY
Valuation and translation adjustmentsPrior1YearInstant48000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant48000000JPY
Net assetsPrior1YearInstant58351000000JPY
Net assetsCurrentQuarterInstant57885000000JPY
Liabilities and net assetsPrior1YearInstant195087000000JPY
Liabilities and net assetsCurrentQuarterInstant204147000000JPY
Net salesPrior1YTDDuration166310000000JPY
Net salesCurrentYTDDuration175575000000JPY
Cost of salesPrior1YTDDuration138761000000JPY
Cost of salesCurrentYTDDuration148442000000JPY
Gross profitPrior1YTDDuration27548000000JPY
Gross profitCurrentYTDDuration27132000000JPY
Selling general and administrative expensesPrior1YTDDuration24150000000JPY
Selling general and administrative expensesCurrentYTDDuration26709000000JPY
Operating incomePrior1YTDDuration3397000000JPY
Operating incomeCurrentYTDDuration423000000JPY
Commission fee noiPrior1YTDDuration23000000JPY
Commission fee noiCurrentYTDDuration23000000JPY
Rent income noiPrior1YTDDuration306000000JPY
Rent income noiCurrentYTDDuration433000000JPY
Insurance income noiPrior1YTDDuration11000000JPY
Insurance income noiCurrentYTDDuration2000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass